Assisting Pulmonary Disease Diagnosis With Ophthalmic Artificial Intelligence Technology
Condition(s) studied
Investigational drug(s) / intervention(s)
Ophthalmic examination: Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
Pulmonary Examination: Various pulmonary examination modalities, including radiography, chest CT, pulmonary function measurement, etc.
Study summary
This study intends to collect ophthalmologic examination results, pulmonary examination results and related indexes from patients with pulmonary disease and control populations, and combine big data analysis and artificial intelligence technology to explore whether new methods can be provided for early screening strategies for pulmonary disease with the aid of ophthalmologic examination, and thus assist in identifying the types of pulmonary disease and determining disease prognosis.
Eligibility
Primary outcome measure(s)
- Area Under the Receiver Operating Characteristic curve — Through study completion, an average of 1 year
Determining the accuracy of diagnosing pulmonary disease with ophthalmic examination
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Zhongshan Ophthalmic Center, Sun Yat-sen University | Guangzhou | Guangdong | Recruiting |
| Guangzhou Kindness Health Care Center (Guangzhou Jiubang Shanxin Clinic Ltd) | Guangzhou | Guangdong | Recruiting |
| the First Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong | Recruiting |
| Shenzhen Third People's Hospital | Shenzhen | Guangdong | Recruiting |
More Zhongshan Ophthalmic Center, Sun Yat-sen University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05847894 on ClinicalTrials.gov ↗ ← All trials in China